<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="retraction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2024.1399853</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Retraction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Retraction: Establishment of criteria for molecular differential diagnosis of MPC and IPM</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<collab>Frontiers Editorial Office</collab>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/228891"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="edited-by">
<p>Approved by: Giuseppe Giaccone, Vice President Global Development, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Frontiers Editorial Office, <email xlink:href="mailto:editorial.office@frontiersin.org">editorial.office@frontiersin.org</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>14</volume>
<elocation-id>1399853</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>03</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Frontiers Editorial Office</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Frontiers Editorial Office</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="retracted-article" xlink:href="10.3389/fonc.2020.614430" ext-link-type="doi">A Retraction of the Original Research Article <article-title>Establishment of criteria for molecular differential diagnosis of MPLC and IPM</article-title> By Wang X, Gong Y, Yao J, Chen Y, Li Y, Zeng Z, Lu Y and Song L (2021). <italic>Front. Oncol.</italic> 10:614430. doi:&#xa0;<object-id>10.3389/fonc.2020.614430</object-id>
</related-article>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="1"/>
<word-count count="93"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Molecular Targets and Therapeutics</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Following publication, the authors contacted the Editorial Office to request the retraction of the cited article, stating that they discovered a fault in their experimental design that rendered the conclusion unreliable. An investigation was conducted in accordance with Frontiers&#x2019; policies that confirmed this; therefore, the article has been retracted.</p>
<p>This retraction was approved by the Chief Editors of Oncology and the Chief Executive Editor of Frontiers. The authors agree to proceed with the retraction and sincerely regret any inconvenience this may have caused to the reviewers, editors and readers of Frontiers in Oncology.</p>
</body>
</article>